When did Summit Therapeutics report Q4 2024 earnings?

Summit Therapeutics (SMMT) reported Q4 2024 earnings on February 24, 2025 before market open.

What were Summit Therapeutics's Q4 2024 revenue and EPS?

Summit Therapeutics reported revenue of - and diluted EPS of $-0.08 for Q4 2024.

Did Summit Therapeutics beat estimates in Q4 2024?

EPS beat the consensus estimate of $-0.08 by $0.00.

Where can I find Summit Therapeutics's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001599298-25-000048) directly on SEC EDGAR. The filing index links above go to sec.gov.

Summit Therapeutics SMMT Q4 2024 Annual earnings

Reported February 24, 2025 · Before market open

Revenue-Diluted EPS-$0.08Beat by $0.00

EPS estimate-$0.08

Next report

Aug 10, 2026 (In 4 weeks)

Revenue estimate$108.8K

EPS estimate-$0.26

Financials

Q4 2024

Income statement

See full

Revenue-—

Operating income-$65.6M-81.2%

Net income-$61.2M-67.4%

EPS (diluted)-$0.09-800%

Balance sheet

See full

Cash & equivalents$16.3M+46.9%

Total debt$7.2M-93.2%

Total equity$388.7M+400%

Total assets$435.6M+115%

Cash flow

See full

Operating cash flow-$48.7M-150%

CapEx$14.0K+600%

Free cash flow-$48.7M-150%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$13.16B+618%

Enterprise value$13.15B+582%

Returns & leverage

See full

Return on equity-94.9%-43.4pp

Debt / equity0×-1.3×

Current ratio10.2×+0.9×

Versus estimates

Diluted EPS

Q1 2026-$0.24Beat by $0.09 Q4 2025-$0.29Miss by $0.19 Q3 2025-$0.31Miss by $0.13 Q2 2025-$0.76Miss by $0.67 Q1 2025-$0.09Beat by $0.00

Q4 2024-$0.08Beat by $0.00

Ask the moment Summit Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Summit Therapeutics report Q4 2024 earnings?: Summit Therapeutics (SMMT) reported Q4 2024 earnings on February 24, 2025 before market open.
What were Summit Therapeutics's Q4 2024 revenue and EPS?: Summit Therapeutics reported revenue of - and diluted EPS of $-0.08 for Q4 2024.
Did Summit Therapeutics beat estimates in Q4 2024?: EPS beat the consensus estimate of $-0.08 by $0.00.
Where can I find Summit Therapeutics's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001599298-25-000048) directly on SEC EDGAR. The filing index links above go to sec.gov.